Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

Table 3 Recommended treatment regimens for hepatitis C virus GT1 infection

Recommendation category	Treatment option/s	Treatment regimens
Preferred	LDV + SOF ± RBV	LDV + SOF for 12 wk
		In treatment-naïve patients having HCV RNA < 6 million IU/mL in whom cirrhosis has been conclusively ruled out by transient elastography (FibroScan) or biopsy: LDV + SOF for 8 wk
		In treatment-experienced cirrhotic patients/patients with decompensated liver disease/postliver transplant patients: LDV + SOF + RBV for 12 wk (or) LDV + SOF for 24 wk if RBV is ineligible
Alternative	SOF + DCV ± RBV	SOF + DCV for 12 wk (addition of RBV may be considered if cirrhosis has not been conclusively ruled out)
		In patients with compensated cirrhosis: SOF + DCV ± weight-based RBV for 24 wk
		In patients with decompensated cirrhosis: SOF + DCV + RBV for 12 wk (or) SOF + DCV for 24 wk if RBV is ineligible
Not recommended	Due to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended.

SOF: Sofosbuvir; LDV: Ledipasvir; DAAs: Direct-acting antivirals; DCV: Daclatasvir; RBV: Ribavirin; RNA: Ribonucleic acid.